

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

003300-696

U.S. APPLICATION NO. (if known, see 37 CFR 1.57)
09/700,177INTERNATIONAL APPLICATION NO.
PCT/SE99/00824INTERNATIONAL FILING DATE
12 May 1999PRIORITY DATE CLAIMED
14 May 1998

TITLE OF INVENTION

BIOLOGICALLY ACTIVE COMPOSITION

JCN6 Rec'd PCT/PTO 29 JAN 2001

APPLICANT(S) FOR DO/EO/US

ÅKE LINDAHL, HÅKAN HAGSLÄTT, CATHARINA HEIMAN & RICHARD BRYLAND

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (Supplemental)
 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. A **FIRST** preliminary amendment.
 14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
 15. A substitute specification.
 16. A change of power of attorney and/or address letter.
 16. Other items or information: Petition for Extension of Time (one month)
Transmittal of Formal Drawing.



01/31/2001-MNGUYEN-00000016-09700177

01 FC:154

130.00 DP

02 FC:115

110.00 DP

527 Rec'd PCT 13 NOV 2000

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

003300-696

U.S. PATENT AND TRADEMARK OFFICE 37 C.F.R. 1.51

097700177

INTERNATIONAL APPLICATION NO.
PCT/SE99/00824INTERNATIONAL FILING DATE
12 May 1999PRIORITY DATE CLAIMED
14 May 1998

TITLE OF INVENTION

BIOLOGICALLY ACTIVE COMPOSITION

APPLICANT(S) FOR DO/EO/US

ÅKE LINDAHL, HÅKAN HAGSLÄTT, CATHARINA HEIMAN & RICHARD BRYLAND

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)

6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))

- a. are transmitted herewith (required only if not transmitted by the International Bureau).
- b. have been transmitted by the International Bureau.
- c. have not been made; however, the time limit for making such amendments has NOT expired.
- d. have not been made and will not be made.

8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Signed Declaration will Follow)10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
- A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:

A certified copy of Swedish Application No. 98-01705-6, filed May 14, 1998 was submitted during the international phase of prosecution. Accordingly, it is urged that the claim for priority has been perfected.

U.S. APPLICATION NO. (if known) / see 37 C.F.R. 1.80 09/700177		INTERNATIONAL APPLICATION NO. PCT/SE99/00824	ATTORNEY'S DOCKET NUMBER 003300-696
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5)):			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO		\$1,000.00 (960)	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO		\$860.00 (970)	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO		\$710.00 (958)	
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)		\$690.00 (956)	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)		\$100.00 (962)	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 1,000.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).		20 <input type="checkbox"/> 30 <input type="checkbox"/>	\$
Claims	Number Filed	Number Extra	Rate
Total Claims	29 -20 =	9	X\$18.00 (966) \$ 162.00
Independent Claims	2 -3 =	0	X\$80.00 (964) \$ -
Multiple dependent claim(s) (if applicable)		+\$270.00 (968) \$ -	
TOTAL OF ABOVE CALCULATIONS =		\$ 1,162.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$ -	
		SUBTOTAL =	\$ 1,162.00
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).		20 <input type="checkbox"/> 30 <input type="checkbox"/>	\$ -
		+	
		TOTAL NATIONAL FEE =	\$ 1,162.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +		\$ -	
		TOTAL FEES ENCLOSED =	\$ 1,162.00
		Amount to be: refunded \$	
		charged \$	

- a. A check in the amount of \$ 1,162.00 to cover the above fees is enclosed.
- b. Please charge my Deposit Account No. 02-4800 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Benton S. Duffett, Jr.
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620


SIGNATURE
Benton S. Duffett, Jr.
NAME
22,030
REGISTRATION NUMBER

Patent
Attorney's Docket No. 003300-696

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **BOX PCT**
ÅKE LINDAHL et al) Attention: DO/EO/US
Application No.: Unassigned) Group Art Unit: Unassigned
Filed: November 13, 2000) Examiner: Unassigned
For: BIOLOGICALLY ACTIVE)
COMPOSITION)
)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Application corresponds to International Application No. PCT/SE99/00824,
filed May 12, 1999.

Please amend the Application as indicated.

In the Abstract:

Please add the Abstract of the Disclosure that is provided on a separate sheet.

In the Claims:

Claim 3, lines 1 and 2, delete "any one of claims 1 and 2" and insert --claim 2--.

Claim 4, line 1, delete "any one of claims 1-3" and insert --claim 1--.

Claim 5, line 1, delete "any one of claims 1-3" and insert --claim 1--.

Claim 8, line 1, delete "any one of claims 1-7" and insert --claim 1--.

Claim 9, line 1, delete "any one of claims 1-8, and insert --claim 1--.

Claim 10, lines 1 and 2, delete "any one of claims 1-8" and insert --claim 1--.

Claim 11, lines 1 and 2, delete "any one of claims 1-10" and insert --claim 1--.

Claim 12, lines 1 and 2, delete "any one of claims 1-11" and insert --claim 1--.

Claim 15, lines 1 and 2, delete "any one of claims 1-14" and insert --claim 1--.

Claim 16, lines 1 and 2, delete "any one of claims 1-15" and insert --claim 1--.

Claim 17, lines 1 and 2, delete "any one of claims 1-16" and insert --claim 1--.

Claim 20, lines 1 and 2, delete "any one of claims 18 and 19" and insert

--claim 18--.

Claim 21, lines 1 and 2, delete "any one of the preceding claims" and insert

--claim 1--.

Claim 22, lines 1 and 2, delete "any one of the preceding claims" and insert

--claim 1--.

Claim 25, lines 1 and 2, delete "any one of the preceding claims" and insert

--claim 1--.

27. (Amended) A method according to claim 26, wherein said composition is

[as defined in any one of claims 2-25] comprises a biologically active agent to be released
therefrom, said biologically active agent being dissolved and/or dispersed in a carrier
therefor, wherein said carrier is a liquid and/or solid non-crystalline matrix in which said
biologically active agent is present in a supersaturated state, said supersaturated state being

obtainable by subjecting one or more carrier starting substance(s) to such chemical operation(s) that said liquid and/or solid non-crystalline carrier matrix is provided in which the degree of saturation of said biologically active agent is higher than in said carrier starting substance(s), the biologically active agent being added before said chemical operation(s) and (have) been completed, wherein said higher degree of saturation is the result of such chemical operation(s) that the solubility of the biologically active agent in said matrix is lower than the solubility thereof in said carrier starting substance(s).

Please add the following new Claims 28 and 29:

--28. A composition according to claim 2, wherein said higher degree of saturation is the result of such chemical operation(s) that the degree of dissociation, aggregation and/or degree of protonation of the biologically active agent is different from the degree of dissociation, aggregation and/or degree of protonation of said agent in said carrier starting substance(s).

29. A composition according to claim 19, wherein said monomeric alcohol is propylene glycol.--

REMARKS

The present Amendment modifies the claim format so as to eliminate the use of multiple dependency.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: November 13, 2000

TOS2R0 "2/200/50

Abstract of the Disclosure

The invention relates to a novel biologically active composition which comprises a biologically active agent to be released therefrom, said biologically active agent being dissolved and/or dispersed in a supersaturated state within a carrier, which carrier is a liquid and/or solid non-crystalline matrix, and where the precipitation of said biologically active agent is substantially, or completely, inhibited therein. Said supersaturated state is obtainable by subjecting one or more carrier starting substance(s) to such chemical operation(s) that a matrix is provided in which the degree of saturation of said biologically active agent is higher than the degree of saturation of said biologically active agent in said carrier starting substance(s), the biologically active agent being added either before said chemical operation(s) or after a predetermined point of time, after which the composition thus prepared is further subjected to said chemical operation(s).

BIOLOGICALLY ACTIVE COMPOSITIONTechnical Field

The present invention relates to a biologically active composition from which one or more biologically active components are to be released. More specifically,
5 the invention relates to a biologically active composition wherein the biologically active agent is present in a supersaturated state within a carrier without being precipitated therefrom.

Background of the Invention

From inter alia toxicological points of view, it is often preferred, upon treatment of diseases or symptoms thereof, to deliver drugs directly to their site(s) of action. It is well known that the risks of obtaining detrimental effects of systemic origin are often markedly reduced if a drug is delivered directly to its site(s) of action. Furthermore, systemic delivery often involves metabolism of the drug prior to its appearance at the site of action, which leads to a subsequent reduction of 15 its biological effect. Another important aspect is that in e.g. cases of imminent overdosage, allergic reactions or administration of contraindicating drugs, it is easy to remove topical compositions in contrast to drugs administered per-orally or by injection.

20 As used herein, topical administration comprises inter alia dermal, sub-lingual, gingival, buccal, transdermal, nasal, vaginal and rectal administration, whereby the resulting biological effect may be local and/or systemic.

25 In e.g. dermal, nasal, vaginal, buccal or sub-lingual administration, only a very limited number of drugs are capable of permeating into the human body by themselves at a useful rate. Consequently, a lot of research has been conducted in order to investigate the 30 possibility of both improving traditional non-invasive

delivery techniques and developing novel non-invasive drug delivery systems or devices intended for systemic and/or internal use. Three fundamentally different approaches towards this objective have been disclosed.

5 Firstly, there is the well known possibility of improving the penetration properties of the drug by chemical modification thereof. After the drug has entered the body, its pharmacologically active form is obtained by chemical reaction(s) *in vivo*. However, this so called
10 pro-drug approach is only occasionally a successful alternative. There are several reasons therefor, such as i) the penetration rate of the pro-drug may still be too low, ii) the pro-drug may be toxic or otherwise harmful, or iii) the *in vivo* conversion to the active form of the
15 drug is too slow and/or partially results in inactive or toxic compounds. A distantly related approach is the preparation of an ion pair between a drug and an appropriate counter ion. However, generally such an ion pair does not display any markedly improved penetration
20 rate through human barriers.

Secondly, the properties of the barrier may be changed in order to facilitate the drug delivery. Methods of achieving this are e.g. ultra-sonication, applying of electrical current or the use of so called penetration
25 enhancers in the composition. All of these methods act by disrupting the structure of the barrier, thereby facilitating drug diffusion through the barrier into the body, and/or improving the drug solubility in the barrier. However, the methods involving e.g. heat, ultra-
30 sonication and electrical current are generally not designed for being easily managed by the patient in a convenient manner, and therefore require hospitalisation, which is a major disadvantage with said methods. In addition, all methods which are based on the approach of
35 changing the barrier properties are questionable from a toxicological point of view due to the observations that i) adverse effects on the cells of the barrier have been

T052010//T05260

demonstrated, and ii) a reduction of the protective properties of the barrier also result in increased penetration rate for any substance, not only the drug, that is present at the site of administration. It should
5 also be mentioned, that a majority of the known chemical penetration enhancers require some time for the onset of their action, i.e. display a lag time of action, since they must be established in the barrier before the actual increase in penetration rate is observed.

10 Thirdly, the driving force of the drug for entering the body can be changed. That is, the difference in the electrochemical potential of the drug between the drug reservoir and the body can be increased. Drug delivery systems based on this approach result in a high flux of
15 the drug through the barrier and usually also display a reduced lag time of action.

In methods based on iontophoresis, this approach is utilised by applying an electrical potential gradient across the barrier. Obviously, these methods are mainly
20 suitable for drugs having a net charge and are therefore much less efficient for uncharged and zwitterionic species, since the flux of the two latter species is improved mainly due to e.g. osmotic and electroosmotic driving forces. Iontophoresis methods also have the
25 disadvantage that they may alter the structure of the barrier.

In another approach, the flux of a drug into the body can be enhanced by increasing the chemical potential of the drug in the carrier therefor. This is normally
30 performed by chemical optimisation of the drug composition by adjusting the degree of saturation of the drug in said carrier. The methods based on this approach offer several advantages as compared to the previously mentioned methods, since the flux of the drug is
35 increased in comparison with subsaturated and saturated systems. Furthermore, the properties of the barrier itself are comparatively less affected and the lag time

T0521D1 // 7002/50

of initiation for the pharmacological effect is reduced. There are two particularly important aspects in this approach:

- 5 i) creation of an initial high chemical potential of the drug in the composition
- ii) maintenance of a high chemical potential of the drug in the vicinity of the barrier after the application of the composition.

Therefore, it is usually desirable to prepare
10 pharmaceutical compositions which are saturated with respect of the drug. During application, another important aspect of said composition is that the solubility and diffusion properties of the drug in the used vechicle must preclude depletion of the drug in the
15 vicinity of the barrier. Examples of compositions used for this purpose are microemulsions and emulsions.

Another approach towards keeping the composition saturated is the use of an excess amount of drug (non-solubilised) in the carrier, whereby the drug is
20 subsequently dissolved as it replaces the drug which has penetrated through the barrier.

Yet another approach is the use of a supersaturated composition of the drug. Here, the driving force of the drug to penetrate the barrier is higher than in the
25 saturated composition, since the drug in a supersaturated composition has higher chemical potential in comparison with the corresponding saturated composition. For example, such compositions have been prepared according to the following means or principles: i) dissolving the
30 drug at temperatures and/or pressures at which the solubility of the drug is higher as compared to those temperatures and/or pressures that are relevant for medication (W.L. Chou and S. Riegelmann, *J. Pharm. Sci.*, Vol. 60, No. 9, pp.1281-1302, 1971; WO 97/10812), ii) using
35 solid dispersions or eutectic mixtures or solid drug particles of low degree of crystallinity or of high energy polymorphs (W.L. Chou and S. Riegelmann, *supra*),

T062TU = 22700/60

TOP SECRET//TOP//FOUO//S

iii) mixing a saturated drug solution with a non-solvent therefor, thereby performing a merely physical operation, *in situ* or prior to application, with or without the presence of an antinucleating agent (US 4 940 701, 5 US 4 767 751), iv) solvent evaporation to the surrounding air (Coldman et al., *J. Pharm. Sci.*, 58, No.9 (1969), pp 1098-1102), v) solvent penetration into the human body, vi) water uptake into the composition from the human body, vii) pH-changes in the composition caused by H⁺-uptake from the human body, or viii) dispersing an aqueous solution or emulsion of a drug in an aqueous dispersion of a polymer latex (Lichtenberger et al., "Polymer films from aqueous polymer dispersions as carriers for transdermal delivery of lipophilic drugs", 10 15th Int Symp CRS:Basel 1988; Abstr 89). An important common denominator of iv)-vii) is that the supersaturation is not initially present in the composition, and is therefore *de facto* not accomplished until the composition is applied to a human body. 15 Furthermore, a major problem with all the compositions i)-viii) is that the drug generally precipitates in a relatively short time, in which case the saturation degree becomes markedly reduced.

In DD 217 989, a subsaturated solution of a drug is 25 mixed with a solution or suspension of an acrylate, after with the mixture so prepared is dried, whereby a supersaturated composition is obtained by use of an exclusively physical operation.

W.L. Chou and S. Riegelmann (*J. Pharm. Sci.*, Vol.58, 30 No. 12, pp.1505-1510, 1969) have reported that in matrices of higher molecular weight polyethylene glycols, precipitation of a supersaturated drug dissolved therein is usually sluggish. In said document, supersaturation was obtained through either direct melting or solvent 35 concentration, i.e. by use of typical physical operations.

As prior art, reference is also made to WO 97/00670, which discloses a composition based on ingredients similar to those utilized in the present invention. However, said reference does not disclose or suggest any supersaturated state or even less those features and measures of the present invention which have been found crucial to impart a stable, supersaturated state to such a composition.

Other prior art of interest is WO 97/10812, which discloses a method for preparing supersaturated systems, wherein an admixture of drug and polymer having a calculated depressed melting temperature is heated to a temperature above said calculated temperature, whereby the drug is dissolved in the polymeric material and supersaturation thereof is obtained through cooling of the heated solution. However, the present invention is not related to preparation of supersaturated systems by exploitation of the calculated depressed melting temperature of an admixture through an entirely physical operation.

Mention can also be made of GB 2 306 885, which utilises the skin's innate ability to buffer applied liquids. Here, a supersaturated system is attained *in situ* by applying a subsaturated drug composition having a pH of 7-12 or 3-4 to skin, where the buffering effect of skin causes a pH change to 4.5-6.5, whereby a supersaturated composition is obtained by means of a change of the degree of protonation of the drug. The preparation of supersaturated systems according to the present invention does not rely on such an exchange of protons.

General Disclosure of the Invention

A novel approach for obtaining a biologically active composition with outstanding delivery rate of its active component(s) has now been developed, wherein said composition comprises a biologically active agent which is present in a substantially stable supersaturated

state. In brief summary, it has been found that by subjecting a carrier starting substance to such chemical operation(s) that a carrier matrix of substantially non-crystalline or amorphous nature is created, in which the 5 degree of saturation of a biologically active agent is higher than the degree of saturation of said agent in the starting carrier substance, a surprisingly stable supersaturated composition can be obtained. In the 10 composition thus prepared, the precipitation of said agent is substantially, or completely, inhibited by said carrier matrix *per se*.

The term "biologically active agent", as used herein, also comprises such progenitors thereto which are readily transformable, e.g. enzymatically and/or 15 hydrolytically, to a biologically active agent *per se*.

Thus, the present invention relates to a novel biologically active composition which comprises a biologically active agent to be released therefrom, said biologically active agent being dissolved and/or 20 dispersed in a supersaturated state within a carrier, which carrier is a liquid and/or solid substantially non-crystalline matrix, and where the precipitation of said biologically active agent is substantially, or completely, inhibited therein.

25 The term "liquid" as used in connection with the present invention should be interpreted in a broad sense, viz as any material being a mobile or viscous liquid, rubber, glass or plastic; thus including solutions, creams, pastes, ointments and gels within the scope of 30 the claims.

The present invention also relates to a method for the preparation of a biologically active composition comprising a biologically active agent dissolved and/or dispersed in a supersaturated state in a carrier therefor 35 as well as to said composition for use as a medicament.

The term "pharmaceutically active agent", as used herein, also comprises such progenitors, e.g. pro-drugs,

0520567727742

which are readily transformable, e.g. enzymatically and/or hydrolytically, to a pharmaceutically active agent *per se*.

One of the objects of the present invention is thus
5 to provide a supersaturated composition which does not display any significant precipitation or loss of effect during long-term storage at room temperature, or even at above or below room temperature, during e.g. months or even years.

10 Another object of the present invention is to provide a supersaturated composition which does not display any significant precipitation or loss of effect during its application to a human or animal patient.

15 Still another object of the present invention is to provide a carrier matrix which is suitable in preparation of a composition having a particularly high degree of supersaturation of a drug (*vide infra*).

20 Yet another object is to provide a stable supersaturated composition which is easily handled and does not require professional assistance upon use thereof.

25 As a result of the high delivery rate of its active component(s), another object of the present invention is to provide a composition which allows for efficient topical treatment, preferably dermal or transdermal administration to small areas, which is a general advantage in the topical administration of drugs.

Detailed Disclosure of the Invention

30 More specifically, the invention refers to a biologically active composition comprising a biologically active agent dissolved and/or dispersed in a carrier therefor, wherein said carrier is a liquid and/or solid substantially non-crystalline matrix in which said
35 biologically active agent is present in a supersaturated state and in which the precipitation of said biologically active agent is substantially, or completely, inhibited

09250107/27/2024

by said matrix, said supersaturated state being obtainable, or obtained, by subjecting one or more starting substance(s) to such chemical operation(s) that a liquid and/or solid substantially non-crystalline
5 matrix is provided in which the degree of saturation of said biologically active agent is increased in comparison with the degree of saturation of said agent in the starting substance(s), the biologically active agent being added before said chemical operation(s) has (have)
10 been completed.

As used herein, the term "chemical operation" refers to a measure resulting in formation or cleavage of covalent bonds. Said formation or cleavage may comprise or by indirect means yield a pH change of the
15 composition, thus involving a proton transfer which in some cases may be regarded as formation or cleavage of a covalent bond. However, such a pH change is in this context the result of a chemical operation which does not merely comprise a proton transfer but which also
20 comprises formation or cleavage of other types of covalent bonds.

In one embodiment of the invention, said supersaturated state is obtainable by subjecting one or more carrier starting substance(s) to such chemical
25 operation(s) that a matrix is provided in which the degree of saturation of said biologically active agent is higher than the degree of saturation of said biologically active agent in said carrier starting substance(s), the biologically active agent being added at a predetermined
30 point of time after said chemical operation(s) have been initiated, after which the composition thus prepared is further subjected to said chemical operation(s).

Other preferable embodiments of the composition claimed will be defined in the claims or referred to below in connection with the method.
35

Thus, the present invention also refers to a method for the preparation of a biologically active composition

T052701/227001/60

comprising a biologically active agent dissolved and/or dispersed in a carrier therefor, wherein

a carrier starting substance, or a mixture of two or more different starting substances, is (are) subjected to

- 5 such chemical operation(s) that a liquid and/or solid non-crystalline carrier matrix is formed, in which the degree of saturation of a biologically active agent is higher than the degree of saturation of said agent in said carrier starting substance(s), said biologically
10 active agent being added before said chemical operation(s) has (have) been completed and in an amount such that a supersaturated state is obtained. Generally this means that said chemical operation(s) is (are) initiated either:

- 15 i) in the presence of said biologically active agent; or
ii) in the absence of said biologically active agent, after which said agent at a predetermined point of time is added and the
20 composition thus prepared is further subjected to said chemical operation(s);

addition of said biologically active agent in both i) and ii) being made using an amount such that a supersaturated state is obtained.

- 25 In one embodiment of the invention, the degree of saturation of a biologically active agent is higher as a result of such chemical operation(s) that a liquid and/or solid non-crystalline carrier matrix is formed, in which the solubility of a biologically active agent is lower
30 than the solubility of said agent in said carrier starting substance(s).

In another embodiment of the invention, the degree of saturation of a biologically active agent is higher as a result of such chemical operation(s) that a liquid

- 35 and/or solid non-crystalline carrier matrix is formed, in which the degree of dissociation, aggregation and/or degree of protonation of a biologically active agent is

T05270-2/T00250

different from the degree of dissociation, aggregation and/or degree of protonation of said agent in said carrier starting substance(s). As a non-limiting example, this embodiment allows formation *in situ* of a suitably

- 5 charged, e.g. protonated or deprotonated, or non-charged form of said biologically active agent, which form has a higher skin penetration rate in comparison with the form of said agent present before said chemical operation(s) is initiated.

10 In yet another embodiment of the invention, the degree of saturation of a biologically active agent is increased by such chemical operation(s) that both the two embodiments set forth above are practised either simultaneously or consecutively.

15 In one embodiment of the invention, said biologically active agent is being added, either above or around room temperature, in solid and/or liquid, i.e. melted, state and is subsequently dissolved in said starting substance(s) either above or around room

20 temperature.

In another embodiment of the invention, said biologically active agent is being added, either above or around room temperature, as a solution or dispersion and is subsequently dissolved in said starting substance(s) either above or around room temperature.

According to the present invention, above room temperature is a temperature above about 25°C, such as about 25-200°C, preferably about 30-150°C. Examples of other suitable temperatures are about 35-100°C and

30 40-80°C.

The particular addition method used for said agent can be any common inclusion technique available to a person skilled in the art, and said solution or dispersion of the biologically active agent can be prepared *inter alia* by solvent evaporation, freeze-drying or by use of any one of the methods *i)-vii)* (*vide supra*).

T052700" /Z/T03/760

Preferably, in the composition according to the invention as well as in the method for preparation thereof, the starting substance(s) act(s) as solvent or dispersing medium.

- 5 Said chemical operation(s) generally involve(s) one or more chemical reactions, preferably etherifying, esterifying, hydrolysis, substitution, addition, elimination, oligomerising and/or polymerising reactions, wherein polymerising reactions are the most preferred.
- 10 Said carrier starting substance(s), which is subsequently subjected to said operation(s) above, is selected from monomers, acids, such as mono-, di- or triacids or higher acids, alcohols, including mono-, di- or triols, ketones, aldehydes, amines, amides,
- 15 anhydrides, lactides, glycolides, saccharides and derivatives thereof, acrylic or acrylamide type compounds, such as methyl methacrylate, monomers of PEO-diacrylate (PEO-polyethylene oxide), cyanoacrylate, acrylate saccharides, including acrylate starch, acrylate
- 20 lactate, acrylate glycolate, isocyanates, ethylene oxide, propylene oxide, pyrrolidone, PEO-diacrylate, ethylene-vinyl acetate, monomers of organic siloxanes and oligomers, polymers or prepolymers thereof. As indicated earlier, one, two or more of the above substances can be
- 25 chosen, thereby allowing the formation of co-polymers and/or higher polymers.

It is to be understood by a person skilled in the art, that said chemical operation(s) is performed to such a degree of completion that a desired non-crystalline carrier matrix is obtained, which matrix is optimal for a particular biologically active agent in a particular context. Thus, all of the starting substance(s) present when said chemical operation(s) is initiated do not necessarily have to react completely in order to carry out the invention, as long as the desired degree of supersaturation is attained.

T052701-ZZT03Z60

In a preferred embodiment of the present invention, the carrier starting substances are an acid and an alcohol, said formed non-crystalline matrix comprising, or being, an ester and/or polyester thereof. In a more 5 preferred embodiment, said carrier starting substances are citric acid and propylene glycol.

In an alternative embodiment, the starting substance is one bi- or multi-functional substance only, which when subjected to said chemical operation(s) provides the 10 desired non-crystalline carrier matrix by chemical reaction(s) with itself. In a non-limiting disclosure, such a starting substance can be citric acid, which when subjected to esterifying conditions provides a non-crystalline citric acid ester and/or polyester matrix 15 according to the invention.

According to the present invention, suitable chemical operation(s) involve(s) subjecting said carrier starting substance(s) to such polymerising conditions which are normally used, according to standard reference literature, for the selected starting substance(s) or combinations thereof. Furthermore, such polymerising conditions should be chosen in order to optimise the manufacturing procedure, in respect of e.g. the stability 20 of said agent, manufacturing time and degree of supersaturation, for the particular biologically active 25 agent used. Typically, said conditions comprise e.g. subjecting said carrier starting substance(s) to a temperature from around -50°C to around 300°C, preferably around 0-150°C. Other examples of useful temperature 30 ranges are 20-100°C and 50-80°C. Said temperature ranges are particularly preferred when the starting substance(s) are a mixture of citric acid and propylene glycol. Naturally, said chemical reaction(s) are selected and 35 performed so that in each case the maximum or optimum delivery rate of said biologically active agent is obtained.

03276917 "032901

Preferably, said chemical reaction(s) is (are) performed for a time period of from 1 minute to 6 months, more preferably from 0,5 hours to 4 months. As an example, said time period may also be from 1 hour to 3 months or from 1 to 2 months.

The predetermined point of time (*vide supra*), as measured after said chemical operation(s) has (have) been initiated, is generally from 1 minute to 6 months, preferably from 0,5 hours to 4 months, after which the composition thus obtained is further subjected to said chemical operation(s) for a time period of about from 1 minute to 6 months, preferably from 0,5 hours to 4 months. As an example, said predetermined point of time may also be from 1 hour to 3 months or from 1 to 2 months.

The used chemical reaction(s) in the present invention preferably comprise a polymerisation reaction and most preferably such reaction in which ether and/or ester bonds are formed. Other preferred polymerisation reactions are step polymerisation reactions and chain polymerisation reactions comprising either radical initiation, ionic initiation or coordination complex initiation.

According to the present invention, some of the monofunctional starting substance(s) above, e.g. monoacids and -alcohols, can also be used to form a non-crystalline matrix consisting of e.g. monoesters and monoethers. Monofunctional monomers can also be introduced into said chemical reaction as a means of modifying the reaction or controlling the end point thereof.

As already indicated, in order to efficiently inhibit precipitation of the supersaturated biologically active agent, said formed matrix is of a substantially non-crystalline, or amorphous, nature. Polymers, co-polymers, oligomers and ethers or esters of the previously

outlined starting substance(s) (*vide supra*) are particularly useful for this purpose.

- A number of different parameters have been of interest in the development of the present invention. As
5 an example of such a parameter, a reaction which results in the formation of a non-crystalline matrix, consisting of molecules with a larger molecular weight than the starting substance(s), can result in an increase of the thermodynamic potential of the form of the biologically
10 active agent(s) which diffuse(s) through a biological barrier, such as skin. During the progression of such a reaction, a lowered solubility of the biologically active agent in said matrix will in many instances be observed, albeit it must here be emphasized that said lowered
15 solubility may not always be necessary in order to yield an increased thermodynamic potential of the form of the biologically active agent which *de facto* diffuses through the skin. Moreover, the degree of dissociation, aggregation and/or protonation of the biologically active
20 agent, e.g. as a result of pH changes, is often relevant in eliciting the desired increased thermodynamic potential of the form(s) of said agent diffusing through the skin.

- Non-limiting examples of biologically active agents,
25 preferably pharmaceutically active agents, which are suitable for use in the present invention are e.g., guanosides, corticosteroids, psychopharmaceutical hormones, oxicams, peptides, proteins as well as agents selected from the group of antibiotics, antivirals,
30 antimicrobials, anticancer agents, antifungals, oestrogens, antiinflammatory agents, neuroleptic agents, melanocyte stimulants and gland stimulants, preferably stimulators of sebaceous and pilo-sebaceous glands, and agents with an effect on mast cell secretion.

- 35 In an alternative embodiment of the present invention, the biologically active agent may also react reversibly with said starting substance(s) in such a

manner that e.g. esters, ethers, co-polymers and/or other conjugates are formed. Thus, this embodiment allows preparation of a non-crystalline matrix containing both said biologically active agent in a substantially stable supersaturated state and conjugate(s) thereof, whereas said conjugate(s) can be present in either a subsaturated, saturated or supersaturated state.

Alternatively, said conjugate(s) can be present in a supersaturated state, whereas said biologically active agent is present in either a subsaturated, saturated or supersaturated state. Therefore, in the case where said biologically active agent is a drug, this particular embodiment allows formation *in situ* of a corresponding drug progenitor, which may either function as a pro-drug or as a depot of the supersaturated drug, or a combination of both. As an example of this embodiment, a biologically active agent containing a carboxylic acid or alcoholic functionality may form an ester with said carrier starting substance(s) when a mixture thereof is subjected to esterifying conditions.

In another embodiment of the present invention, the starting substance(s) can be an ester and/or polyester matrix, or an ether and/or polyether matrix, to which a biologically active agent is added, after which the dispersion or solution formed is subjected to a hydrolysis reaction providing a liquid and/or solid non-crystalline carrier matrix in which the degree of saturation of said biologically active agent is higher than the degree of saturation of said biologically active agent in said starting substance(s), a stable supersaturated dispersion or solution thus being obtained. As a non-limiting example of such an embodiment, the starting substance(s) may consist of several esters and/or polyesters, of which one or several is much more readily hydrolysed in comparison with all other substances present, including the biologically active agent.

09285772901

In yet another embodiment of the invention, a minor amount of said starting substance(s) is subjected to said chemical conditions, preferably a polymerisation, in the presence of a solvent, whereby a supersaturated one- or

5 two-phase matrix is formed, such as a liquid/solid non-crystalline matrix.

However, in the most preferred embodiment, the biologically active composition consists of one liquid or solid phase only.

- 10 As earlier indicated, in another embodiment of the present invention the carrier starting substance(s) can be subjected to said chemical reaction(s), preferably a polymerisation, in advance and without the presence of said biologically active agent. By using this approach, a prefabricated liquid and/or solid non-crystalline matrix
- 15 is provided, to which matrix a biologically active agent can subsequently be added at a predetermined point of time by use of any suitable inclusion method, such as e.g. mixing, heating, freeze-drying and/or solvent evaporation, after which the composition thus prepared is
- 20 further subjected to said chemical reaction(s), which is (are) either identical or somewhat modified, by e.g. use of a lower reaction temperature or further addition of one or more of the previously outlined starting
- 25 substance(s), in comparison with the chemical reaction(s) performed initially.

For some biologically active agents it is preferred to prepare a supersaturated composition shortly before administration thereof. Indeed, the present composition

30 is useful for such preparations in addition to it being suitable for supersaturated compositions intended for long-term storage and application. As for the choice of a suitable degree of supersaturation of the biologically active agent in the present composition, it is known from

35 the laws of thermodynamics that within a given period of time the danger of precipitation increases with the degree of supersaturation. Still, the present composition

TOP SECRET//EYD/DOE/SD

is also suitable in such particular preparations where a very high degree of supersaturation is desirable, despite a somewhat increased danger of precipitation.

The scope of the present invention is not limited to
5 the specific embodiments disclosed above, and the disclosed invention may optionally be combined with the methods i)-vii) (*vide supra*) in any suitable manner, if deemed necessary in any particular case. As a non-limiting example, the pH of the composition prepared
10 according to the invention may optionally be subsequently modified by inclusion of a suitable acidic or basic compound, if useful in a particular context.

The following non-limiting example will illustrate the present invention further.

Brief description of the enclosed diagrams

Diagram 1 shows the amount of permeated metronidazole as a function of time for a subsaturated composition A₀, a saturated composition C and the supersaturated compositions B₁ and B₂.

Diagram 2 displays the amount of metronidazole permeated from compositions X1-X4 and Y1-Y4.

Experimental part

- 10 Example 1; demonstrating an increased thermodynamic potential by using the method of the present invention:

The degree of supersaturation was characterised by the permeation rate of the biologically active agent through a membrane (Silastic sheeting NRV, 0,005 inches, serial #HH055353) by using a Franz diffusion cell (FDC-400 Crown Glass Company) with a cell opening area of 2,011 cm². All permeation rate measurements were performed at 25°C and deaerated H₂O was used as acceptor phase on the opposing side of the membrane. The donor and acceptor phase were both sealed with parafilm, and each experiment was performed in triplicate.

Starting substances: citric acid (CiAc) and propylene glycol

- 25 Four parts of CiAc and six parts of propylene glycol were added to a sealable container at room temperature, after which said container was sealed. The resulting mixture was stirred with a magnetic stirrer and the temperature was raised to and maintained at 80°C until all CiAc was dissolved, after which the solution was 30 allowed to attain room temperature. This solution was denoted A. Solid metronidazole was then added to the solution A in a 5:95 ratio (w/w), after which the metronidazole was dissolved by magnetic stirring at room temperature. The solution thus prepared was then split 35 into two solutions denoted A₀ and B, respectively.

As reference, a solution of 4 parts of CiAc and 6 parts of propylene glycol was prepared as above. Solid metronidazole in a 7,5:92,5 ratio (w/w) was added, and the mixture was stirred at room temperature for three 5 days. After centrifugation resulting in sedimentation of non-dissolved metronidazole, the obtained supernatant thus consisted of a saturated metronidazole composition, denoted C. The obtained final ratio between metronidazole and CiAc/propylene glycol was 7:93 (w/w).

10 The underlying principles behind the compositions A-C were the following:

A₀ is a subsaturated mixture of a pharmaceutically active agent and carrier starting substances which is not actively subjected to polymerisation;

15 in B, the starting substances are subjected to polymerisation conditions in the presence of a pharmaceutically active agent; and

20 in C, the permeation rate for a saturated solution of a pharmaceutically active agent in a matrix of said carrier starting substances is illustrated.

The compositions B and C were then treated as follows:

B was split into two compositions, which were stored at 70°C for one month (B₁) and two months (B₂), 25 respectively, after which time period the permeation rate measurements were performed on the formed compositions B₁ and B₂, respectively.

The compositions A₀ and C were used directly after the preparation thereof.

30 The measured permeation rates are depicted in the enclosed Diagram 1.

Diagram 1 shows that a considerably higher permeation rate is obtained in the compositions B₁ and B₂, as compared to any one of the compositions A or C. This 35 increased permeation rate is in turn clear evidence that the thermodynamic potential of metronidazole is significantly higher in the compositions B₁ and B₂ in

01290177-01290177

comparison with any one of the compositions A₀ or C. Here, it is important to note that the compositions A₀ and B are initially the same.

- In summary, this example shows that supersaturation of the initially subsaturated composition is attained upon polymerisation. Indeed, further polymerisation results in an even higher permeation rate, i.e. a higher thermodynamic potential, as is illustrated by B₁ and B₂.
- 10 Example 2; demonstrating the precipitation preventing properties of the carrier matrix of the present invention:

A Franz diffusion cell as disclosed above was used under conditions similar to those of example 1, unless otherwise noted. Permeation rate experiments were performed for 21 h. As a reference, the permeation rate from the saturated composition C in example 1 was determined to be 46 µg per 21 h in a Franz diffusion cell experiment, as depicted in Diagram 1. The experiments 20 were all analysed by use of spectrophotometry. The results are depicted in diagram 2.

In order to determine its water solubility, an excess of metronidazole was added to water, after which the mixture was stirred for 3 days at room temperature.

- 25 Analysis by spectrophotometry was performed after sedimentation and centrifugation, and a resulting solubility of s=0.82% (w/w) was obtained.

Four supersaturated water solutions of metronidazole were then manufactured, each one having a degree of 30 saturation (DS = concentration/solubility) of 1.3, 1.6, 2.0 and 2.5, respectively. They were prepared by heating the corresponding amount of metronidazole in water to 80°C for 30 min under stirring, followed by equilibration to room temperature, thereby yielding supersaturated 35 solutions. The time for precipitation of metronidazole to occur (t_p) upon storage at room temperature was monitored

T062701 * 22/09/2002 6B

by visual inspection, and the results are shown in Table 1.

Table 1. Time for precipitation of metronidazole from a
5 supersaturated solution thereof in water.

Solution	metronidazole conc. % (w/w)	DS*	t_p
1	1.06	1.3	5 days < t_p < 14 days
2	1.31	1.6	2 h < t_p < 17 h
3	1.65	2.0	3 h < t_p < 3.5 h
4	2.05	2.5	0.5 h < t_p < 1 h

*DS=1 equals 0.82 % (w/w) metronidazole in water (*vide supra*), as determined by spectrophotometry

- 10 A composition X was manufactured by mixing 4 parts of CiAc and 6 parts of propylene glycol (starting substances) at room temperature in a glass container which was subsequently sealed. The temperature was raised to and maintained at 80°C under stirring for about 45
15 min. The resulting solution was kept at room temperature for about 30 min, and was then split into 4 separate solutions. An appropriate amount of metronidazole (see Table 2) was subsequently added to each solution, followed by heating of the mixture at 80°C for about 40
20 min, after which the resulting compositions were allowed to attain room temperature, thereby yielding the supersaturated compositions X1-X4. Directly after their preparation, the compositions X1-X4 were investigated by Franz diffusion cell measurements (see example 3).
25 A sample was taken from each respective composition X1-X4. These four samples were each kept at 70°C for 3 weeks, thereby yielding the compositions Y1-Y4 (see Table 2). Y1-Y4 were also examined in Franz diffusion cell experiments (see example 3).

T05B205/Z/100/63

Table 2. Degree of saturation of metronidazole in the compositions X1-X4 and Y1-Y4.

metronidazole conc. % (w/w)	Composition	DS*	Composition	DS*
8.0	X1	1.16	Y1	1.62
9.0	X2	1.23	Y2	1.86
10.0	X3	1.54	Y3	2.02
11.0	X4	1.59	Y4	2.18

*The permeation rate at saturation was assumed to be
5 46 µg per 21 h.

The DS values shown in Table 2 were obtained by use of Franz diffusion cell measurements, and to a person skilled in the art, it is well known that the permeation 10 rate of a compound through a Silastic membrane in a Franz cell diffusion cell experiment is a direct measure of the thermodynamic potential of said compound. Moreover, a direct correlation between the thermodynamic potential and the degree of saturation (DS) can often be assumed.
15 Therefore, the equation

DS = permeation rate/permeation rate at saturation
was therefore assumed to be valid when estimating the DS values.

20 The t_p -values for the compositions Y1-Y4 according to the present invention were then investigated in the same manner as described above. These investigations showed that the t_p value for all the compositions Y1-Y4 exceeds 6 weeks. At the time of filing the present application,
25 no precipitation had yet been observed. Indeed, the precipitation preventing properties of the carrier matrix according to the present invention were clearly substantiated, particularly in comparison with the t_p values depicted in Table 1 above.

Example 3; further evidence of increased thermodynamic potential attained in accordance with the present invention:

These experiments were performed in order to further substantiate the degree of saturation of metronidazole in the compositions X1-X4 and Y1-Y4. The Franz diffusion cell experiments were performed under the same conditions as in example 1 (*vide supra*), and the results are shown in Diagram 2.

10




Diagram 2. Amount of metronidazole permeated from compositions X1-X4 and Y1-Y4.

15 As depicted above, Diagram 2 shows that the chemical operation subjected to the compositions X1-X4 upon manufacturing of the compositions Y1-Y4 resulted in an increased thermodynamic potential of metronidazole, as is directly evidenced through the increased permeation rate.
20 The permeation rate for a Y composition has increased approximately 40% in comparison with its corresponding X composition.

In summary, it is clearly realised that biologically active compositions which are prepared or obtainable in accordance with the present invention are useful as medicaments. Furthermore, the biologically active
5 compositions according to the invention are also useful in a non-medicinal context, such as in cosmetic skin products. More specifically, said compositions should be highly efficient in dermal application to a mammal, preferably man, as well as in any general application
10 where a biological barrier is to be penetrated by a biologically active agent.

CLAIMS

1. A biologically active composition comprising a biologically active agent to be released therefrom, said biologically active agent being dissolved and/or dispersed in a carrier therefor, wherein said carrier is a liquid and/or solid non-crystalline matrix in which said biologically active agent is present in a supersaturated state, said supersaturated state being obtainable by subjecting one or more carrier starting substance(s) to such chemical operation(s) that said liquid and/or solid non-crystalline carrier matrix is provided in which the degree of saturation of said biologically active agent is higher than in said carrier starting substance(s), the biologically active agent being added before said chemical operation(s) has (have) been completed.
2. A composition according to claim 1, wherein said higher degree of saturation is the result of such chemical operation(s) that the solubility of the biologically active agent in said matrix is lower than the solubility thereof in said carrier starting substance(s).
3. A composition according to any one of claims 1 and 2, wherein said higher degree of saturation is the result of such chemical operation(s) that the degree of dissociation, aggregation and/or degree of protonation of the biologically active agent is different from the degree of dissociation, aggregation and/or degree of protonation of said agent in said carrier starting substance(s).

T05270/ZZT05270/60

4. A composition according to any one of claims 1-3, wherein said biologically active agent is added before said chemical operation(s) has (have) been initiated.

5. 5. A composition according to any one of claims 1-3, wherein said biologically active agent is added at a predetermined point of time after said chemical operation(s) has (have) been initiated, the composition thus obtained then being further subjected to said
10 chemical operation(s).

6. A composition according to claim 5, wherein said predetermined point of time is from 1 minute to 6 months, preferably from 0,5 hours to 4 months after said chemical
15 operation(s) has (have) been initiated.

7. A composition according to claim 6, wherein the composition is further subjected to said chemical operation(s) for a time period of about from 1 minute to
20 6 months, preferably from 0,5 hours to 4 months.

8. A composition according to any one of claims 1-7, wherein said starting substance(s), or said formed non-crystalline matrix, act(s) as a solvent or dispersing
25 medium.

9. A composition according to any one of claims 1-8, wherein said biologically active agent is added as a solid and/or liquid which is subsequently dissolved in
30 said carrier.

10. A composition according to any one of claims 1-8, wherein said biologically active agent is added in the form of a solution or dispersion.

097007/270050

11. A composition according to any one of claims 1-10, wherein said biologically active agent is added above or around room temperature.

5 12. A composition according to any one of claims 1-11, wherein said chemical operation(s) comprise one or more chemical reactions.

10 13. A composition according to claim 12, wherein said chemical reaction(s) comprise etherifying, esterifying, hydrolysis, substitution, addition, elimination, oligomerising and/or polymerising reactions.

15 14. A composition according to claim 13, wherein said chemical reaction(s) is (are) selected and performed so as to provide optimal delivery rate of said biologically active agent.

20 15. A composition according to any one of claims 1-14, wherein said chemical operation(s) involve(s) subjecting said carrier starting substance(s) to a temperature of from around -50°C to around 300°C, preferably around 0-150°C.

25 16. A composition according to any one of claims 1-15, wherein said chemical operation(s) is (are) conducted for a time period of from 1 minute to 6 months, preferably from 0,5 hours to 4 months.

30 17. A composition according to any one of claims 1-16, wherein said carrier starting substance, or mixture of two or more different carrier starting substances, is selected from monomers, acids, such as mono-, di- or triacids or higher acids, alcohols, including mono-, di- 35 or triols, ketones, aldehydes, amines, amides, anhydrides, lactides, glycolides, saccharides and derivatives thereof, acrylic or acrylamide type

T062101*22700760

compounds, such as methyl methacrylate, monomers of PEO-diacrylate, cyanoacrylate, acrylate saccharides, including acrylate starch, acrylate lactate, acrylate glycolate, isocyanates, ethylene oxide, propylene oxide, 5 pyrrolidone, PEO-diacrylate, ethylene-vinyl acetate, monomers of organic siloxanes, and oligomers, polymers or prepolymers thereof.

18. A composition according to claim 17, wherein the 10 acid is a monomeric acid and the alcohol is a monomeric alcohol, said non-crystalline matrix comprising an ester and/or polyester thereof.

19. A composition according to claim 18, wherein 15 said monomeric acid is citric acid.

20. A composition according to any one of claims 18 and 19, wherein said monomeric alcohol is propylene glycol.

21. A composition according to any one of the preceding claims, which consists of one liquid or solid phase only.

25 22. A composition according to any one of the preceding claims, wherein the biologically active agent is a pharmaceutically active agent.

23. A composition according to claim 22, wherein the 30 pharmaceutically active agent is selected from the group consisting of guanosides, corticosteroids, psychopharmaceutical hormones, oxicams, peptides, proteins, antibiotics, antivirals, antimicrobials, anticancer agents, antifungals, oestrogens, 35 antiinflammatory agents, neuroleptic agents, melanocyte stimulants and gland stimulants, preferably stimulators

1052100-2/700/60

of sebaceous and pilo-sebaceous glands, and agents with an effect on mast cell secretion.


24. A composition according to any one of claims 22
5 and 23 for use as a medicament.

25. A composition according to any one of the preceeding claims for topical, preferably dermal application to a mammal, preferably man.

10 26. A method for the preparation of a biologically active composition comprising a biologically active agent dissolved and/or dispersed in a carrier therefor, wherein
15 a carrier starting substance, or a mixture of two or more different carrier starting substances, is (are) subjected to such chemical operation(s) that a liquid and/or solid non-crystalline carrier matrix is formed, in which the degree of saturation of said biologically active agent is higher than in said carrier starting substance(s), said biologically active agent being added before said chemical operation(s) has (have) been completed and in an amount such that a supersaturated state is obtained.

25 27. A method according to claim 26, wherein said composition is as defined in any one of claims 3-25.

Diagram 1



**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.
003300-696

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

BIOLOGICALLY ACTIVE COMPOSITION

the specification of which

(check one)

is attached hereto;
 was filed on May 12, 1999 as
Application No. PCT/SE99/00824
and was amended on _____;
(if applicable)

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

COMBINED DECLARATION AND POWER OF ATTORNEY


Attorney's Docket No.

003300-696

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Sweden	9801705-6	14 May 1998	YES <u>X</u> NO _____
			YES _____ NO _____

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	R. Danny Huntington	27,903	Gerald F. Swiss	30,113
Robert S. Swecker	19,885	Eric H. Weisblatt	30,505	Charles F. Wieland III	33,096
Platon N. Mandros	22,124	James W. Peterson	26,057	Bruce T. Wieder	33,815
Benton S. Duffett, Jr.	22,030	Teresa Stanek Rea	30,427	Todd R. Walters	34,040
Norman H. Steppn	22,716	Robert E. Krebs	25,885	Ronni S. Jilions	31,979
Ronald L. Grudziecki	24,970	William C. Rowland	30,888	Harold R. Brown III	36,341
Frederick G. Michaud, Jr.	26,003	T. Gene Dillahunt	25,423	Allen R. Baum	36,086
Alan E. Kopecki	25,813	Patrick C. Keane	32,858	Steven M. duBois	35,023
Regis E. Sluter	26,999	B. Jefferson Boggs, Jr.	32,344	Brian P. O'Shaughnessy	32,747
Samuel C. Miller, III	27,360	William H. Benz	25,952	Kenneth B. Leffler	36,075
Robert G. Mukai	28,531	Peter K. Skiff	31,917	Fred W. Hathaway	32,236
George A. Hovanec, Jr.	28,223	Richard J. McGrath	29,195		
James A. LaBarre	28,632	Matthew L. Schneider	32,814		
E. Joseph Gess	28,510	Michael G. Savage	32,596		



21839


and: none

Address all correspondence to:

Benton S. Duffett, Jr.
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

21839Address all telephone calls to: Benton S. Duffett, Jr. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR <u>ÅKE LINDAHL</u>	SIGNATURE 	DATE 3004-12-20
RESIDENCE Skurup, Sweden	SEX	CITIZENSHIP Sweden
POST OFFICE ADDRESS Ringduvevägen 50, 274 33 Skurup, Sweden		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>HÅKAN HAGSLÄTT</u>	SIGNATURE 	DATE 2001-01-15
RESIDENCE Bjärred, Sweden	SEX	CITIZENSHIP Sweden
POST OFFICE ADDRESS Assesorsvägen 10, 237 31 Bjärred, Sweden		

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

003300-696

FULL NAME OF THIRD JOINT INVENTOR, IF ANY CATHARINA BENEDIKTSÖN		SIGNATURE <i>(Signature)</i>	DATE 06.12.22
RESIDENCE Malmö, Sweden		CITIZENSHIP Sweden	
POST OFFICE ADDRESS Kilian-Zoëlgatan 11A, 217 56 Malmö, Sweden			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY RICHARD BRYLAND			
RESIDENCE Malmö, Sweden		SIGNATURE <i>Richard Bryland</i>	DATE 06.12.22
CITIZENSHIP Sweden			
POST OFFICE ADDRESS V. Rönneholmsvägen 60B, 217 41 Malmö, Sweden			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF TENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			